Inhibrx Biosciences, Inc. INBX
Set alert
As of Nov 2, 2:18 PM ET
- YTD
- -9.27%
- 1 year
- -12.22%
- Open
- 72.45
- Prev close
- 71.78
- Mkt cap
- 1.05B
- Vol
- 123.51K
- Avg vol
- 301.77K
- EPS
- -8.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 70.87
- High
- 73.49
- Forward P/E
- -8.21
- Beta
- 3.82
- Short ratio
- 13.62
- Inst. own
- 90.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2026
- 50-d avg
- 102.89
- 200-d avg
- 92.16
- 1y target
- 266.67
5D chart
Signals (108)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:50 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:10 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:15 PM | 5 days ago |
| RSI: Oversold | Oct 28, 12:00 PM | 5 days ago |
| RSI: Oversold | Oct 28, 11:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 10:45 AM | 5 days ago |
| RSI: Oversold | Oct 28, 10:20 AM | 5 days ago |
| RSI: Oversold | Oct 28, 10:05 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 6 days ago |
| RSI: Overbought | Oct 27, 2:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 6 days ago |
| RSI: Overbought | Oct 27, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 6 days ago |
News
5 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
6 days ago defenseworld.net
Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.47 and traded…
2 weeks ago prnewswire.com
Inhibrx Announces Participation in Upcoming Scientific Conferences
SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of…
4 weeks ago defenseworld.net
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
1 month ago marketbeat.com
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical…
1 month ago defenseworld.net
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) rose 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $101.44 and last…
1 month ago defenseworld.net
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price was up 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as…
1 month ago defenseworld.net
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem bought 5,000 shares of Inhibrx Biosciences stock in a transaction on Wednesday, September 23rd. The stock was purchased…
1 month ago defenseworld.net
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem purchased 5,000 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was purchased…
1 month ago fool.com
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held…
1 month ago seekingalpha.com
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma…
1 month ago seekingalpha.com
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk…
1 month ago benzinga.com
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.
1 month ago benzinga.com
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
1 month ago reuters.com
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
1 month ago prnewswire.com
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with…
-
1 month ago benzinga.com
Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage
1 month ago prnewswire.com
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
2 months ago prnewswire.com
Inhibrx Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical…
3 months ago seekingalpha.com
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027…
3 months ago prnewswire.com
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic…
3 months ago zacks.com
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.
-
4 months ago benzinga.com
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic…
4 months ago prnewswire.com
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic…
-
5 months ago benzinga.com
Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate
Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the analyst consensus estimate of $(1.79) by 20.11 percent. This is a 23.21 percent increase over losses…
5 months ago benzinga.com
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.
-
5 months ago benzinga.com
Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC
Today, the Company presented preliminary data from 53 patients (25 in the INBRX-106 combination arm and 28 in the control arm) with a data cutoff of May 7, 2026, representing the evaluable population…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
5 months ago benzinga.com
Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage…
6 months ago benzinga.com
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
6 months ago benzinga.com
GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares rose 14.1% after beating estimates and raising sales guidance.
6 months ago benzinga.com
Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results
US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69%. Utilities sector jumps 1.4%, financials only up 0.1%.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
6 months ago benzinga.com
'Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say' - Reuters
https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/
-
6 months ago benzinga.com
Inhibrx Announces Updated Interim Data From Phase1/2 Ozekibart Combination With Folfiri Evaluation
Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC. The Company also plans to…
6 months ago benzinga.com
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.
-
6 months ago benzinga.com
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150
Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.
10 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
11 months ago benzinga.com
Earnings Scheduled For November 14, 2025
Earnings Scheduled For November 14, 2025
1 year ago benzinga.com
Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?
Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading strengthened market conviction that the Federal Reserve will cut interest rates by 25 basis points at its…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago benzinga.com
Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October
Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October
1 year ago benzinga.com
Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday
Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
1 year ago benzinga.com
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying